Alle verbonden artikelen

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pagina's : 897-905

Are there several kinds of palliative care?

Auteurs : Klastersky J
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(4)
Pagina's : 355-6

The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study.

Auteurs : Azim HA, Botteri E, Renne G, Dell orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart-Gebhart M, Goldhirsch A, Viale G, Peccatori F
Jaar : 2012
Journal : Acta oncol (Stockholm)
Volume : 51(5)
Pagina's : 653-61

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

Auteurs : Ignatiadis M, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(7)
Pagina's : 1653-5

Pemetrexed salvage chemotherapy for NSCLC: implementation study].

Auteurs : Jungels C, Berghmans T, Meert AP, Lafitte JJ, Scherpereel A, Sculier JP
Jaar : 2012
Journal : Rev Mal Respir
Volume : 29(1)
Pagina's : 21-7

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.

Auteurs : Farhat FS, Tfayli A, Fakhruddin N, Mahfouz R, Otrock ZK, Alameddine RS, Awada A, Shamseddine A
Jaar : 2012
Journal : Crit Rev Oncol Hematol
Volume : 84(2)
Pagina's : 149-60

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Auteurs : Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, Mcgale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart-Gebhart M, Pritchard K
Jaar : 2012
Journal : Lancet
Volume : 379(9814)
Pagina's : 432-44

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Auteurs : Bleiberg H, Vandebroek A, Deleu I, Vergauwe P, Rezaei Kalantari H, DHaens G, Paesmans M, Peeters M, Efira A, Humblet Y
Jaar : 2012
Journal : Acta Gastroenterol Belg
Volume : 75(1)
Pagina's : 14-21

Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives.

Auteurs : Akasbi Y, Awada A, Arifi S, Mellas N, El Mesbahi O
Jaar : 2012
Journal : Bull Cancer
Volume : 99(10)
Pagina's : 92-9

EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Auteurs : Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk HJ, Vermorken JB
Jaar : 2012
Journal : Radiother Oncol
Volume : 105(2)
Pagina's : 238-40

Chemoprevention for breast cancer.

Auteurs : Bozovic-Spasojevic I, de Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pagina's : 329-339

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Auteurs : Burstein HJ, Piccart-Gebhart M, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA
Jaar : 2012
Journal : J. Clin. Oncol.
Volume : 30(18)
Pagina's : 2179-82

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Auteurs : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Jaar : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pagina's : R70

Prevention and management of major side effects of targeted agents in breast cancer.

Auteurs : Metzger Filho O, Saini KS, Azim HA, Awada A
Jaar : 2012
Journal : Crit Rev Oncol Hematol
Volume : 84(1)
Pagina's : e79-85

Bone metastasis in breast cancer: The story of RANK-Ligand.

Auteurs : Azim HA, Kamal NS
Jaar : 2012
Journal : J Egypt Natl Canc Inst
Volume : 24(3)
Pagina's : 107-14

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Auteurs : Baselga J, Campone M, Piccart-Gebhart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
Jaar : 2012
Journal : N Engl J Med
Volume : 366(6)
Pagina's : 520-9

The confusion around neuroendocrine tumors.

Auteurs : Hendlisz A, Deleporte A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(4)
Pagina's : 431-2

Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies.

Auteurs : Azim HA, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(7)
Pagina's : 834-42

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Auteurs : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 2997-3006

Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.

Auteurs : Maréchal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, Hendlisz A, Demols A, Franchimont D, Verset G, Van Houtte P, Van de Stadt J, Van Laethem JL
Jaar : 2012
Journal : Ann Oncol
Volume : 23(6)
Pagina's : 1525-30